Moxifloxacin hydrochloride ( DrugBank: Moxifloxacin )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
113筋ジストロフィー1
299嚢胞性線維症1

113. 筋ジストロフィー


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04821063
(ClinicalTrials.gov)
April 13, 202126/3/2021Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC IntervalA Randomized, Partially Double-Blind, Four-Period, Four-Treatment, Crossover Study Investigating the Placebo-Corrected Effects of a Therapeutic Dose (100 mg) and a Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval in Healthy Male and Female SubjectsDuchenne and Becker Muscular Dystrophy;Polycytemia VeraDrug: ITF2357 10 mg/mL;Drug: Placebo;Drug: Moxifloxacin HydrochlorideItalfarmacoNULLCompleted18 Years55 YearsAll31Phase 1Canada

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01910415
(ClinicalTrials.gov)
June 201319/7/2013Phase 1, QT/QTC Interval Study in Healthy SubjectsA Phase 1, Randomized, Placebo and Active Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of Lumacaftor in Combination With Ivacaftor on the QT/QTc Interval in Healthy SubjectsCystic FibrosisDrug: Lumacaftor;Drug: Lumacaftor Placebo;Drug: Ivacaftor;Drug: Ivacaftor Placebo;Drug: moxifloxacin hydrochlorideVertex Pharmaceuticals IncorporatedNULLCompleted18 Years55 YearsBoth200Phase 1Netherlands